Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Parasitol ; 67(4): 1732-1739, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36260194

ABSTRACT

PURPOSE: Leishmaniasis is a neglected infectious disease affecting millions of people worldwide. Visceral leishmaniasis (VL), caused by Leishmania infantum and Leishmania donovani, is one of the main clinical forms of the disease and fatal if not treated promptly and properly. Despite being available for the last 70 years, current drugs used in the treatment of leishmaniasis have serious problems as they have high toxicity, require long-term administration and cause serious side-effects, leading to the emergence of resistant and relapse cases. Therefore, there is an urgent need for the discovery of novel antileishmanial molecules and the development of new treatment regimens. The drug used for chemotherapy of B-cell malignancies, Ibrutinib, an inhibitor of Bruton's Tyrosine Kinase (BTK), can offer a new therapeutic perspective due to the functions of BTK on intracellular signaling mechanism of macrophages, which are the primary resident cell for Leishmania. Hence, the study aimed to evaluate ibrutinib as a potential anti-Leishmanial drug. METHOD: In this study, we evaluated the antileishmanial effect of Ibrutinib by in vitro L. infantum infection model using macrophages, with cell viability assay, parasite rescue assay, real-time qPCR. RESULTS: We showed that Ibrutinib was significantly more effective than the Glucantime against L. infantum. In addition, our data revealed that Ibrutinib inhibited parasite growth and load without impairing macrophage viability. CONCLUSIONS: Consequently, due to its efficacy and safety, Ibrutinib may be a promising candidate for the treatment of VL caused by L. infantum as a host-targeted drug.


Subject(s)
Antiprotozoal Agents , Leishmania donovani , Leishmania infantum , Leishmaniasis, Visceral , Leishmaniasis , Humans , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/parasitology , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use
2.
Sci Rep ; 11(1): 14204, 2021 07 09.
Article in English | MEDLINE | ID: mdl-34244543

ABSTRACT

The pandemic of 2019 caused by the novel coronavirus (SARS-CoV-2) is still rapidly spreading worldwide. Nucleic acid amplification serves as the gold standard method for confirmation of COVID-19 infection. However, challenges faced for diagnostic laboratories from undeveloped countries includes shortage of kits and supplies to purify viral RNA. Therefore, it is urgent to validate alternative nucleic acid isolation methods for SARS-CoV-2. Our results demonstrate that a concentrated viral lysis amplification buffer (vLAB) prepared with the nonionic detergent IGEPAL enables qualitative detection of SARS-CoV-2 by direct Reverse Transcriptase-Polymerase Chain Reaction (dRT-PCR). Furthermore, vLAB was effective in inactivating SARS-CoV-2. Since this method is inexpensive and no RNA purification equipment or additional cDNA synthesis is required, this dRT-PCR with vLAB should be considered as an alternative method for qualitative detection of SARS-CoV-2.


Subject(s)
COVID-19 Nucleic Acid Testing , COVID-19 , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2/genetics , Specimen Handling , COVID-19/diagnosis , COVID-19/genetics , Humans , Sensitivity and Specificity
3.
Turkiye Parazitol Derg ; 45(2): 88-94, 2021 06 07.
Article in English | MEDLINE | ID: mdl-34103283

ABSTRACT

Objective: This study aimed to determine the differences between the gene expression profiles of Leismania major and Leishmania infantum promastigotes through comparative analysis of gene expressions. Methods: Cell culture of L. major (MHOM/IL/80) and L. infantum (MHOM/MA/67/ITMAP/263) cell lines was performed. Afterwards, total RNA isolation and cDNA synthesis were performed and fold changes in the expression levels of 30 genes that play a role in metabolic pathways and nucleic acid synthesis and co-expressed in two species were evaluated by reverse transcriptase polymerase chain reaction. Functions of genes were determined using LeishDB and KEGG databases. Results: In this study, profiles of protein-coding 30 genes expressed in L. major and L. infantum promastigotes were evaluated and significant differences were found between the two species (p<0.001). There was a significant fold change in the expression levels of 29% of genes common in the two species. The expression levels of nine genes in L. major were found to be markedly higher than those of L. infantum (fold change >1). These genes include phosphoglycan beta 1.3 galactosyltransferase-like, lathosterol oxidase-like, fatty acid elongase, 3-oxo-5 alpha-steroid 4-dehydrogenase, calpain-like cysteine peptidase, acetyl-coA synthetase, 3'-nucleotidase/nuclease, 3'-nucleotidase/nuclease precursor and 3-ketoacyl-coA thiolase-like. When the functions of the proteins that correspond to the genes common in the two species were examined in detail using the databases, it was determined that these genes play role in lipid, protein, carbohydrate and nucleic acid metabolic functions of the parasite. Conclusion: Alterations in the expression profiles of genes common to L. major and L. infantum species may cause differences in the virulence, pathogenesis, clinical features and treatment modality between these parasite species. In addition, evaluation of gene profiles is important in the selection of species-specific or common targets for vaccine and drug studies.


Subject(s)
Leishmania infantum/genetics , Leishmania major/genetics , Life Cycle Stages/genetics , Transcriptome , Animals , Humans , Leishmania infantum/growth & development , Leishmania major/growth & development , Protozoan Proteins/genetics , Species Specificity
4.
Acta Trop ; 208: 105517, 2020 Apr 28.
Article in English | MEDLINE | ID: mdl-32360239

ABSTRACT

Gene expression profiling in mouse models of leishmaniasis has given useful information to understand the molecular pathways active in lesions and to discover new diagnostic/therapeutic targets. Although the host response plays a critical role in protection from leishmaniasis and promoting disease severity, there are still unexplained aspects in the mechanism of non-healing cutaneous lesions, which need biomarkers for both targeted- therapy and diagnosis. To address this, transcriptional profiling of the skin lesions obtained from BALB/c mice infected with Leishmania major and healthy skin from naïve mice were evaluated by bioinformatics analysis, and then the results were validated by Revers Transcriptase-PCR. Five genes among the up-regulated differentially expressed genes named FCGR4, CCL4, CXCL9, Arg1 and IL-1ß were found to have relatively high diagnostic value for CL due to L. major. Pathway analysis revealed that Triggering Receptor Expressed On Myeloid Cells 1 (TREM1) signaling pathways are active in cutaneous lesions, providing new insights for the understanding and treatment of leishmaniasis.

5.
Breast Cancer ; 27(6): 1082-1095, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32472473

ABSTRACT

BACKGROUND: Cancer is a major cause of death worldwide and most of the therapeutic approaches are relatively ineffective in eliminating cancer especially due to drug resistance. As an alternative, therapy with live microorganisms can induce a robust proinflammatory and anti-cancer immune response in the microenvironment of the tumor. In the present study, we aimed to establish a model for taking the advantages of immune responses against intracellular protozoan parasites for cancer treatment. METHODS: Leishmania infantum and L. tropica were used in our study as agents of visceral and cutaneous forms of the infection, respectively. After establishing 4T1 breast cancer in mice groups, live-attenuated L. infantum (At-Li) and live-attenuated L. tropica (At-Lt) treatments were performed and results were evaluated according to tumor volume, immune markers and histological examination. RESULTS: Live-attenuated Leishmania strains regressed 4T1-breast cancer in mice and are nonpathogenic, and these strains induce an immune response against 4T1 breast cancer. It is shown that At-Lt is found to be more effective than At-Li in breast cancer treatment using different methods included in the study as analyses of immune parameters, and histopathological examination in tumor tissue besides spleen cells. The tumor grew more slowly by the immune-stimulant effect of live-attenuated Leishmania parasites. CONCLUSION: This promising therapy should be investigated for optimization in further studies with different cancer types and L. tropica may be designed to express antigens to enhance tumor antigen-specific responses, which may further improve efficacy and immune memory development.


Subject(s)
Breast Neoplasms/therapy , Cancer Vaccines/administration & dosage , Leishmania infantum/immunology , Leishmania tropica/immunology , Leishmaniasis Vaccines/administration & dosage , Animals , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Cell Line, Tumor/transplantation , Disease Models, Animal , Female , Humans , Immunologic Memory , Injections, Intravenous , Injections, Subcutaneous , Mice , Tumor Microenvironment/immunology , Vaccines, Attenuated/administration & dosage
6.
Mol Biochem Parasitol ; 237: 111277, 2020 05.
Article in English | MEDLINE | ID: mdl-32348840

ABSTRACT

Cryptosporidiosis is an obligate intracellular pathogen causing diarrhea. Merozoite egress is essential for infection to spread between host cells. However, the mechanisms of egress have yet to be defined. We hypothesized that Cyclic GMP-Dependent Protein Kinase G (PKG) may be involved in Cryptosporidium egress. In this study, Cryptosporidium parvum PKG was silenced by using antisense RNA sequences. PKG-silencing significantly inhibited egress of merozoites from infected HCT-8 cells into the supernatant and led to retention of intracellular forms within the host cells. This data identifies PKG as a key mediator of merozoite egress, a key step in the parasite lifecycle.


Subject(s)
Cryptosporidium parvum/genetics , Cyclic GMP-Dependent Protein Kinases/genetics , Host-Parasite Interactions/genetics , Merozoites/genetics , Protozoan Proteins/genetics , Cell Line , Cryptosporidium parvum/enzymology , Cryptosporidium parvum/growth & development , Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic GMP-Dependent Protein Kinases/metabolism , Epithelial Cells/parasitology , Gene Expression , Gene Silencing , Humans , Merozoites/enzymology , Protozoan Proteins/antagonists & inhibitors , Protozoan Proteins/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...